## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims**

- 1. (Canceled)
- 2. (Canceled)
- 3. (Canceled)
- 4. (Canceled)
- 5. (Canceled)
- 6. (Canceled)
- 7. (Canceled)
- 8. (Canceled)
- 9. (Canceled)
- 10. (Canceled)
- 11. (Canceled)
- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)
- 15. (Canceled)
- 16. (Canceled)
- 17. (Canceled)
- 18. (Canceled)
- 19. (Canceled)
- 20. (Canceled)
- 21. (Canceled)
- 22. (Canceled)
- 23. (Canceled)
- 24. (Canceled)
- 25. (Canceled)
- 26. (Canceled)
- 27. (Canceled)

- 28. (Canceled)
- 29. (Canceled)
- 30. (Canceled)
- 31. (Canceled)
- 32. (Amended) A method of preparing a cancer vaccine, comprising:
- (a) contacting a neoplastic cell population with a first marker dye,
- (b) contacting an antigen presenting cell population with a second marker dye, wherein said first dye is different from said second dye,
- (c) contacting said neoplastic cell population and said antigen presenting cell populations population with one another under conditions that promote cell fusion,
- (d) purifying the resultant hybrid cell population by <u>fluorescence activated</u> cell sorting, and
- (e) resuspending the resultant hybrid cell population in a pharmaceutically acceptable vehicle;

wherein said cell sorting does not involve antibiotic or metabolic selection and the diversity of the starting cell populations is preserved in the resultant hybrid cell population.

- 33. (Canceled)
- 34. (Canceled)
- 35. (Amended) The method of claim 32<del>, 33 or 34,</del> wherein the resultant cell population contains less than 10% of its total population as reactant cells.
- 36. (Amended) The method of claim 32<del>, 33 or 34,</del> wherein the resultant cell population contains less than 5% of its total population as reactant cells.
  - 37. (Canceled)
  - 38. (Canceled)
  - 39. (Canceled)
  - 40. (Canceled)
- 41. (Amended) The method of claim 32<del>, 33 or 34,</del> wherein said pharmaceutically acceptable vehicle is normal saline.
  - 42. (Canceled)
  - 43. (Canceled)
  - 44. (Previously Presented) A method of preparing a tumor vaccine, comprising:

- (a) contacting a tumor cell population with a first dye,
- (b) contacting a dendritic cell population with a second dye,
- (c) contacting said tumor cell population and said dendritic cell population with one another under conditions that promote cell fusion,
  - (d) purifying the resultant hybrid cell population by cell sorting, and
- (e) resuspending the resultant hybrid cell population in a pharmaceutically acceptable buffer;

wherein said cell sorting does not involve antibiotic or metabolic selection, the resultant cell population contains less than 5% reactant cells, and diversity of the starting cell populations is preserved in the resultant hybrid cell population.